# A Study to Evaluate the Safety and Efficacy of NT-88

> **NCT07509801** · NA · NOT_YET_RECRUITING · sponsor: **Guangzhou Manjing biomedicine technology co., ltd** · enrollment: 60 (estimated)

## Conditions studied

- Heart Failure With Mildly Reduced Ejection Fraction

## Interventions

- **DRUG:** Conventional therapeutic drugs
- **DRUG:** NT-88

## Key facts

- **NCT ID:** NCT07509801
- **Lead sponsor:** Guangzhou Manjing biomedicine technology co., ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509801, "A Study to Evaluate the Safety and Efficacy of NT-88". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07509801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*